EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MGMT, NUPR1, NDRG2, and GLI1 Gene Promoter Methylation in Glioblastoma Tissues and Association with Clinical Characteristics and Therapeutic Outcomes

Mariam M Gabr, Sherihan G AbdelHamid iD, Lobna R Ezz El Arab, Menha Swellam iD, Nadia M Hamdy iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27020763 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Mariam M Gabr und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ain Shams University Hospitals, Abassia, Cairo 11566, Egypt. Hauptthemen laut MEDLINE: Glioblastoma, DNA Methylation, Promoter Regions, Genetic, Tumor Suppressor Proteins. Die Arbeit nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: STDF, Science, Technology & Innovation Funding Authority, Science Technology & Innovation Funding Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most prevalent and devastating form of primary brain tumors in adults, with dismal survival despite advancements in treatment modalities. The current study sought to develop clinically significant prognostic models for GBM patients by comprehensively profiling MGMT, NUPR1, NDRG2, and GLI1 gene promoter methylation in GBM tissues vs. non-neurooncological disease (NND) and their association with clinical characteristics and therapeutic outcome. This was further evaluated by in silico functional enrichment analysis. NUPR1, NDRG2, and GLI1 gene promoter methylation were significant epigenetic discriminators between GBM and NND. However, NDRG2 methylation was the sole independent predictor for neoplastic lesions (OR = 1.71, 95% CI [1.25–3.57], p = 0.028). Multivariable Cox regression analysis revealed that NUPR1 promoter hypermethylation was significantly correlated with a lower risk of mortality (HR = 0.96, 95% CI [0.96–0.99], p = 0.002), while multiple tumor sites were linked to an increased risk of mortality in the univariate model (HR = 4.44, 95% CI [1.42–13.88], p = 0.01). A heatmap correlation matrix identified a robust positive correlation among the MGMT and NUPR1 methylation status (r = 0.93, p < 0.001). NUPR1 and MGMT promoter hypermethylation was associated with a favorable response to temozolomide therapy. Patients with NUPR1 and MGMT hypermethylation exhibited extended OS and PFS compared to those with hypomethylation levels, whereas GLI1 and NDRG2 hypermethylation were linked to shorter PFS. In conclusion, the multi-faceted epigenetic panel adopted in the current study captures different aspects of GBM biology and moves towards a more comprehensive model that reflects the molecular heterogeneity of GBM as insights for personalized therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaDNA MethylationPromoter Regions, GeneticTumor Suppressor ProteinsDNA Modification MethylasesDNA Repair EnzymesZinc Finger Protein GLI1Brain NeoplasmsBasic Helix-Loop-Helix ProteinsHumansFemaleMaleMiddle AgedPrognosisGene Expression Regulation, NeoplasticAdultAgedNeoplasm Proteins

Stichwörter der Autor:innen

DNA methylationEpigeneticsGLI1MGMTNDRG2NUPR1bioinformaticsglioblastoma (GBM)in silico

Substanzen

Tumor Suppressor ProteinsNDRG2 protein, humanDNA Modification MethylasesMGMT protein, humanDNA Repair EnzymesZinc Finger Protein GLI1Basic Helix-Loop-Helix ProteinsNUPR1 protein, humanGLI1 protein, humanNeoplasm Proteins

Autor:innen und Institutionen

  • Ain Shams University Hospitals, Abassia, Cairo 11566, Egypt.
  • Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Ain Shams University, Abassia, Cairo 11566, Egypt.
  • Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Abassia, Cairo 11566, Egypt.
  • Biochemistry Department, Biotechnology Research Institute, High Throughput Molecular and Genetic Laboratory, Central Laboratories Network and the Center for Excellences for Advanced Sciences, National Research Centre, D…

ORCID-Profile: Sherihan G AbdelHamid, Menha Swellam, Nadia M Hamdy

Förderung

  • STDF
  • Science, Technology & Innovation Funding Authority
  • Science Technology & Innovation Funding Authority

Zitieren

APA

Gabr, M. M., AbdelHamid, S. G., Ezz El Arab, L. R., Swellam, M., & Hamdy, N. M. (2026). MGMT, NUPR1, NDRG2, and GLI1 Gene Promoter Methylation in Glioblastoma Tissues and Association with Clinical Characteristics and Therapeutic Outcomes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020763

Vancouver

Gabr MM, AbdelHamid SG, Ezz El Arab LR, Swellam M, Hamdy NM. MGMT, NUPR1, NDRG2, and GLI1 Gene Promoter Methylation in Glioblastoma Tissues and Association with Clinical Characteristics and Therapeutic Outcomes. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020763

BibTeX
@article{Gabr2026,
  author = {Gabr, Mariam M and AbdelHamid, Sherihan G and Ezz El Arab, Lobna R and Swellam, Menha and Hamdy, Nadia M},
  title = {MGMT, NUPR1, NDRG2, and GLI1 Gene Promoter Methylation in Glioblastoma Tissues and Association with Clinical Characteristics and Therapeutic Outcomes},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27020763}
}
Kostenlos starten →